Medtronic Touts Smooth Covidien Integration, Meaningful Growth
This article was originally published in Clinica
You may also be interested in...
The medtech giant announced 6% revenue growth, led by the cardiac and vascular and diabetes groups, both of which are enjoying strong market demand for new products. Medtronic expects to continue growing revenues by about five percent annually to maintain double-digit earnings growth.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.